Expertise in
9
conditions

Dr. Jignesh D. Dalal

Hematology | Oncology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
33 Years of Experience
Expertise in
9
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

Jignesh Dalal is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 33 years.

Dr. Dalal is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 65 peer reviewed articles and participating in 6 clinical trials. Dr. Dalal is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
View 3 Less Insurance Carriers -

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Additional Areas of Focus

Dr. Dalal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
Enrollment Status: Recruiting
Publish Date: March 25, 2026
Intervention Type: Drug
Study Drugs: Stratum 1, Strata 2, 3, or 4, GVHD Regimen
Study Phase: Phase 1/Phase 2
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Tacrolimus, Methotrexate
Study Phase: Phase 2
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
View 5 Less Clinical Trials

65 Total Publications

A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.
A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.
Journal: Leukemia & lymphoma
Published: August 07, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Valent is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Valent is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Valent is currently accepting new patients.

Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Pohlman is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Pohlman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pohlman is currently accepting new patients.

Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anjali Advani is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Advani is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Advani is board certified in American Board Of Internal Medicine, 2003. Dr. Advani is currently accepting new patients.

Frequently Asked Questions about Dr. Jignesh D. Dalal

How do I make an appointment with Dr. Jignesh D. Dalal?

You can book an appointment with Dr. Jignesh D. Dalal by calling their office at 216-844-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jignesh D. Dalal a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jignesh D. Dalal is classified as an Distinguished expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jignesh D. Dalal specialize in?

While Dr. Jignesh D. Dalal is a Hematology, they have specific expertise in Sickle Cell Disease, Bone Marrow Transplant, and Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jignesh D. Dalal participate in research or clinical trials?

Yes. Dr. Jignesh D. Dalal has published 65 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Jignesh D. Dalal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jignesh D. Dalal accept my insurance?

Dr. Jignesh D. Dalal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-844-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dalal's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile